Drug Libraray

DRACPC ID DRACPC0051

Active Ingredients Bleomycin A6

Description A component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.

Synonyms Bleomycin; Bleomycin A6

Type Small Molecule

Disease Squamous Cell Lung Cancer

Classification

Peptide and derivative

Molecular Formula C60H96N20O21S2

Molecular Weight 1497.7

Active Sequence Not available

Sequence Length Not available

Modification Not available

Structure

Show IUPAC/InChI/SMILES

IUPAC Name [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-5-[[(2S,3R)-1-[2-[4-[4-[3-[4-(3-aminopropylamino)butylamino]propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate

InChI InChI=1S/C60H96N20O21S2/c1-25-38(77-51(80-49(25)64)30(17-36(63)84)72-18-29(62)50(65)90)55(94)79-40(46(31-19-69-24-73-31)99-59-48(44(88)42(86)34(20-81)98-59)100-58-45(89)47(101-60(66)96)43(87)35(21-82)97-58)56(95)74-27(3)41(85)26(2)52(91)78-39(28(4)83)54(93)71-16-9-37-75-33(23-102-37)57-76-32(22-103-57)53(92)70-15-8-14-68-12-6-5-11-67-13-7-10-61/h19,22-24,26-30,34-35,39-48,58-59,67-68,72,81-83,85-89H,5-18,20-21,61-62H2,1-4H3,(H2,63,84)(H2,65,90)(H2,66,96)(H,69,73)(H,70,92)(H,71,93)(H,74,95)(H,78,91)(H,79,94)(H2,64,77,80)/t26-,27+,28+,29-,30-,34-,35+,39-,40-,41-,42+,43+,44-,45-,46-,47-,48-,58+,59-/m0/s1

InChI_Key FOUFFVYWFNBHHH-YNGSZULRSA-N

SMILES CC1=C(N=C(N=C1C(N[C@@H]([C@H](C2=CN=CN2)O[C@@H]3O[C@H]([C@H]([C@@H]([C@@H]3O[C@H]4O[C@@H]([C@H]([C@@H]([C@@H]4O)OC(N)=O)O)CO)O)O)CO)C(N[C@@H]([C@H]([C@@H](C(N[C@@H]([C@H](O)C)C(NCCC5=NC(C6=NC(C(NCCCNCCCCNCCCN)=O)=CS6)=CS5)=O)=O)C)O)C)=O)=O)[C@@H](NC[C@@H](C(N)=O)N)CC(N)=O)N

PubChem CID 9877229

DrugBank Accession Number DB12992

NCI Thesaurus Code C102878

UNII 0B19OCB220 GSRS

CAS 37293-17-7

Drug indication
Bleomycin A6 participated in clinical trials for the treatment of Squamous Cell Lung Cancer.

The drug is not approved.

ClinicalTrials.gov Identifier	Title	Condition or disease	Phase	Purpose
NCT01660399	Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial	Squamous Cell Lung Cancer	Phase 2	Treatment

More clinical information is obtained from ClinicalTrials.gov.